Differences in mortality and causes of death between STEMI and NSTEMI in the early and late phases after acute myocardial infarction
Yasuaki Takeji(Kanazawa University), Kyohei Yamaji(Kokura Memorial Hospital), Yuki Obayashi(Kyoto University), Ryoji Taniguchi(Hyogo Prefectural Amagasaki General Medical Center), Yukihito Sato(Hyogo Prefectural Amagasaki General Medical Center), Hiroki Watanabe(Kyoto University), Natsuhiko Ehara(Kyoto University Hospital), Yutaka Furukawa(Kobe City Medical Center General Hospital), Kenji Andò(Kokura Memorial Hospital), Yukiko Matsumura‐Nakano(Kyoto University), Yusuke Yoshikawa(Kyoto University), Hiroki Shiomi(Kyoto University), Ko Yamamoto(Kyoto University), Satoru Suwa(Juntendo University Shizuoka Hospital), Moriaki Inoko(Hyogo Medical University), Tomoya Onodera(Shizuoka City Hospital), Kazuya Nagao(Nagaoka Red Cross Hospital), Kenji Nakatsuma(Kyoto University), Kazushige Kadota(Kurashiki Central Hospital), Yoshihisa Nakagawa(Shiga University of Medical Science), Takeshi Morimoto(Hyogo Medical University), Mamoru Toyofuku(Japanese Red Cross Society Wakayama Medical Center), Toshihiro Tamura(Tenri Hospital), Takeshi Kimura(Municipal Hirakata City Hospital), Tomohisa Tada(Shizuoka General Hospital), Eri Kato(Kyoto University Hospital), Hiroki Sakamoto(Kokura Memorial Hospital)
Cited by 38
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
|The Lancet Diabetes & Endocrinology|2019|673
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
|Circulation Journal|2019|582
Three-Year Follow-up after Implantation of Metallic Coronary-Artery Stents
|New England Journal of Medicine|1996|507